These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34668944)

  • 1. Association Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure-Lowering Therapy.
    Foy AJ; Filippone EJ; Schaefer E; Nudy M; Ruzieh M; Dyer AM; Chinchilli VM; Naccarelli GV
    JAMA Netw Open; 2021 Oct; 4(10):e2128980. PubMed ID: 34668944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.
    Li J; Somers VK; Gao X; Chen Z; Ju J; Lin Q; Mohamed EA; Karim S; Xu H; Zhang L
    JAMA Netw Open; 2021 Feb; 4(2):e2037554. PubMed ID: 33595663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes.
    Ilkun OL; Greene T; Cheung AK; Whelton PK; Wei G; Boucher RE; Ambrosius W; Chertow GM; Beddhu S
    Diabetes Care; 2020 Aug; 43(8):1878-1884. PubMed ID: 32366577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control.
    Beddhu S; Chertow GM; Cheung AK; Cushman WC; Rahman M; Greene T; Wei G; Campbell RC; Conroy M; Freedman BI; Haley W; Horwitz E; Kitzman D; Lash J; Papademetriou V; Pisoni R; Riessen E; Rosendorff C; Watnick SG; Whittle J; Whelton PK;
    Circulation; 2018 Jan; 137(2):134-143. PubMed ID: 29021322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
    Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
    Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
    JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease.
    Chang TI; Wei G; Boucher R; Kramer H; Chertow GM; Cheung AK; Greene T; Whelton PK; Beddhu S
    Kidney360; 2020 May; 1(5):368-375. PubMed ID: 35369376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
    Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial.
    Lee TC; Cavalcanti RB; McDonald EG; Pilote L; Brophy JM
    Am J Med; 2018 Oct; 131(10):1228-1233.e1. PubMed ID: 29906425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial.
    Ghazi L; Shen J; Ying J; Derington CG; Cohen JB; Marcum ZA; Herrick JS; King JB; Cheung AK; Williamson JD; Pajewski NM; Bryan N; Supiano M; Sonnen J; Weintraub WS; Greene TH; Bress AP
    JAMA Netw Open; 2023 May; 6(5):e2314443. PubMed ID: 37204788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering: Results From the STEP Randomized Trial.
    Yang R; Huang R; Zhang L; Li D; Luo J; Cai J
    Hypertension; 2023 Dec; 80(12):2572-2580. PubMed ID: 37814892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Estimated Pulse Wave Velocity With Survival: A Secondary Analysis of SPRINT.
    Vlachopoulos C; Terentes-Printzios D; Laurent S; Nilsson PM; Protogerou AD; Aznaouridis K; Xaplanteris P; Koutagiar I; Tomiyama H; Yamashina A; Sfikakis PP; Tousoulis D
    JAMA Netw Open; 2019 Oct; 2(10):e1912831. PubMed ID: 31596491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
    Beddhu S; Chertow GM; Greene T; Whelton PK; Ambrosius WT; Cheung AK; Cutler J; Fine L; Boucher R; Wei G; Zhang C; Kramer H; Bress AP; Kimmel PL; Oparil S; Lewis CE; Rahman M; Cushman WC
    J Am Heart Assoc; 2018 Sep; 7(18):e009326. PubMed ID: 30371182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive Blood Pressure Lowering in Individuals With Low Diastolic Blood Pressure and Elevated Troponin Levels in SPRINT.
    Smith C; Berry JD; Scherzer R; de Lemos JA; Nambi V; Ballantyne CM; Kravitz RL; Killeen AA; Ix JH; Shlipak MG; Ascher SB
    J Am Heart Assoc; 2024 Mar; 13(6):e032493. PubMed ID: 38497469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis.
    Pinho-Gomes AC; Azevedo L; Copland E; Canoy D; Nazarzadeh M; Ramakrishnan R; Berge E; Sundström J; Kotecha D; Woodward M; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    PLoS Med; 2021 Jun; 18(6):e1003599. PubMed ID: 34061831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.